WHITE PAPER
Generics: Bridging the Regulatory Gap in Pharmerging and ASEAN Markets
Exploring trends and policies influencing generics while navigating regulatory challenges
Feb 12, 2024
The use of generic drugs is increasing globally, offering a cost-effective alternative to brand-name medications. In 2022, the generics market was valued at around USD 268 billion. The trend is expected to continue as generics improve treatment access and global health outcomes while also reducing healthcare costs. Countries are adopting policies to promote generic medicine use and regulatory bodies are streamlining approval processes.
Read this white paper to explore the market trends and regulatory challenges of the generics landscape in developing economies, with a particular focus on pharmerging and Association of Southeast Asian Nations (ASEAN) markets.
For more information, contact us.
Authors
- Wang Xueying Sherry, Principal, Head of Commercial Regulatory Services
- Wang Kaiye, Consultant, Commercial Regulatory Services
- Frederick Sim, Consultant, Commercial Regulatory Services